Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome

BJU International

Volumn 104, Issue 5, 2009, Pages 657-661

  Kuo, Hann Chorng ^a,c   Chancellor, Michael B ^b  

^a TZU CHI UNIVERSITY   (Taiwan)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Botulinum toxin A; Hydrodistention; Interstitial cystitis; Painful bladder syndrome

Indexed keywords

BOTULINUM TOXIN A; PENTOSAN POLYSULFATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER CAPACITY; BLADDER DISEASE; BLADDER HYDRODISTENTION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTALGIA; CYSTOMETRY; DYSURIA; FEMALE; HEALTH CENTER; HEMATURIA; HUMAN; INJECTION; INTERSTITIAL CYSTITIS; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MUSCLE WEAKNESS; PAINFUL BLADDER SYNDROME; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SURGICAL TECHNIQUE; TREATMENT FAILURE; TREATMENT RESPONSE; URINARY TRACT INFECTION; URINE RETENTION; URODYNAMICS; UROLOGY; VISUAL ANALOG SCALE;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; COMBINED MODALITY THERAPY; CYSTITIS, INTERSTITIAL; DILATATION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; RECURRENCE; TREATMENT OUTCOME;

EID: 68849132576     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08495.x     Document Type: Article

References (22)

1. Hanno PM, Sant GR. Clinical highlights of the National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association scientific conference on interstitial cystitis. Urology 2001 57 (Suppl. 1 2 6
2. Chancellor MB, Yoshimura N. Treatment of interstitial cystitis. Urology 2004 63 (Suppl. 1 85 92
3. Sant GR, Propert KJ, Hanno PM et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyline in patients with interstitial cystitis. J Urol 2003 170 : 810 5
4. Mayer R, Propert KJ, Peters KM et al. A randomized controlled trial of intravesical bacillus Calmette-Geurin for treatment refractory interstitial cystitis. J Urol 2005 173 : 1186 91
5. Ottem DP, Teichman JM. What is the value of cystoscopy with hydrodistension for interstitial cystitis? Urology 2005 66 : 494 9
6. Apostolidis A, Popat R, Yiangou Y et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005 174 : 977 83
7. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with non-neurogenic detrusor overactivity refractory to anticholinergics. Urology 2005 66 : 94 8
8. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 2004 64 : 871 5
9. Kuo HC. Preliminary Results of suburothelial injection of botulinum A toxin in the treatment of chronic interstitial cystitis. Urol Int 2005 75 : 170 4
10. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 2006 49 : 704 9
11. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain response in rats. J Urol 2004 172 : 1529 32
12. Giannantoni A, Di Stasi SM, Nardicchi V et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006 175 : 2341 4
13. Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004 45 : 987 93
14. Cui M, Aoki KR. Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia 2000 20 : 414 8
15. Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol 2008 179 : 1031 4
16. Hanno P. Interstitial cystitis and related diseases. In Walsh PC, Retik AB, Vaughan ED, Wein AJ, Campbell's Urology, 7th edn. Philadelphia : W.B. Saunders, Co., 1998 : 631 62
17. Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987. J Urol 1988 140 : 203 6
18. Lubeck DP, Whitmore K, Sant GR, Alvarez-Horine S, Lai C. Psychometric validation of the O'Leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology 2001 57 (Suppl. 1 62 6
19. Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of interstitial cystitis with intravesical heparin. Br J Urol 1994 73 : 504 7
20. Brady CM, Apostolidis A, Harper M et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 2004 93 : 770 6
21. Steers WD, Tuttle JB. Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 2006 3 : 101 10
22. Chai TC, Zhang CO, Shoenfelt JL, Johnson HW Jr. Warren JW, Keay S. Bladder stretch alters urinary heparin-binding epidermal growth factor and antiproliferative factor in patients with interstitial cystitis. J Urol 2000 163 : 1440 4